VTX2735

Asset

Inhibitor of the NLRP3 inflammasome reducing systemic inflammation

Stage
Phase 2
Modality
Small molecule
Target
NLRP3
1
Indication
1
Trial
1
Developer

Indications

1

In the full profile

  • Targets and what it contains3
  • Owner and partners1
  • Trials1
  • Evidence for its targets3
  • Competitors10
  • Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets